atezolizumab


( Last Updated : November 3, 2021)
Generic Name:
atezolizumab
Project Status:
Pending
Therapeutic Area:
Non-small cell lung cancer
Manufacturer:
Hoffmann-La Roche
Call for patient/clinician input open:
Brand Name:
Tecentriq
Project Line:
Reimbursement Review
Project Number:
PC0269-000
Call for patient/clinician input closed:
Tumour Type:
Lung

Details


Manufacturer Requested Reimbursement Criteria1:
​Atezolizumab as monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for patients with stage II-IIIA (according to AJCC/UICC 7th edition) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 1% of tumour cells (TCs) and do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Atezolizumab as monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for patients with non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 1% of tumour cells (TCs).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.